Clinical trial · Interventional
Intraoperative Imaging of Pulmonary Adenocarcinoma
NCT02653612CI-TRIAL-00031905withdrawnPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study has been terminated, without having enrolled any participants
Summary
Brief summary (as posted)
The goal is to improve surgery by preventing tumor cells from being left behind at the time of surgery. This includes finding residual tumor cells in the wound after surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EC17 imaging contrast agent | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental Arm
- description
- This cohort will receive the contrast agent
- interventionNames
- Drug: EC17 imaging contrast agent
Primary outcomes (2)
- measure
- Margin assessment
- timeFrame
- At the time of surgery
- description
- Percentage of surgeries which detect tumor cells at the surgical margin
- measure
- Lymph node assessment
- timeFrame
- 4 hours
- description
- Number of residual tumor cells in the lymph nodes detected via intraoperative imaging of a FR-targeted fluorescent contrast agent
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * lung cancer * surgical candidate * operable * resectable Exclusion Criteria: \- no allergies to contrast dyes
References
Publications (0)
Data not yet available
No reference posted for this study.